key: cord-0929955-v7vla4ho
authors: Khan, Nabeel; Mahmud, Nadim
title: Effectiveness of SARS-CoV-2 vaccination in a Veterans Affairs Cohort of Inflammatory Bowel Disease Patients with Diverse Exposure to Immunosuppressive Medications
date: 2021-05-25
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.05.044
sha: df5e20ecee7082f71e227c43aede20a4b96521c0
doc_id: 929955
cord_uid: v7vla4ho

Background and Aims Vaccination against SARS-CoV-2 has rapidly expanded, however clinical trials excluded patients taking immunosuppressive medications such as those with inflammatory bowel disease (IBD). Therefore, we explored real-world effectiveness of COVID-19 vaccination on subsequent infection in IBD patients with diverse exposure to immunosuppressive medications. Methods This was a retrospective cohort study of patients in the Veterans Health Administration with IBD diagnosed prior to 12/18/20, the start date of the VHA patient vaccination program. IBD medication exposures included 5-aminosalicylic acid, thiopurines, anti-tumor necrosis factor biologic agents, vedolizumab, ustekinumab, tofacitinib, methotrexate, and corticosteroid use. We used inverse probability weighting and Cox regression with vaccination status as a time-updating exposure, and computed vaccine effectiveness from incidence rates. Results The cohort comprised 14,697 patients, 7,321 of whom received at least one vaccine dose (45.2% Pfizer, 54.8% Moderna). The cohort had median age 68 years, was 92.2% male, 80.4% white, and 61.8% with ulcerative colitis. In follow-up data through April 20, 2021, unvaccinated individuals had the highest raw proportion of SARS-CoV-2 infection (197 [1.34%] versus 7 [0.11%] fully vaccinated). Full vaccination status, but not partial vaccination status, was associated with a 69% reduced hazard of infection relative to an unvaccinated status (hazard ratio [HR] 0.31, 95% confidence interval [CI] 0.17-0.56, p<0.001), corresponding to an 80.4% effectiveness. Conclusion Full vaccination (>7 days after the 2nd dose) against SARS-CoV-2 infection has an approximately 80.4% effectiveness in a broad IBD cohort with diverse exposure to immunosuppressive medications. These results may serve to increase patient and provider willingness to pursue vaccination in these settings.

To evaluate the real-world effectiveness of SARS-CoV-2 vaccination in a large IBD population, many of which were taking immunosuppressive medications.

Full vaccination, but not partial vaccination, against SARS-CoV-2 was significantly associated with reduced infection, and no meaningful differences were noted in comparisons of key immunosuppressive medication classes.

This study cohort comprised of a predominantly older male population and there remains a possibility of residual confounding.

Full vaccination effectively reduces SARS-CoV-2 infection in a large IBD cohort, many of which were on immunosuppressive medications, which should promote patient and provider willingness to pursue immunization in this setting.

The SARS-CoV-2 pandemic is a grave threat to public health with more than 28 million people reported to have been infected and more than half a million deaths in the US alone as of April 2, 2021. 1 Inflammatory Bowel Disease (IBD), comprising of Ulcerative Colitis (UC) and Crohn's Disease (CD), is a chronic inflammatory disorder of the gastrointestinal tract of unknown etiology. The pathophysiology of IBD involves dysregulation of the mucosal immune system and is usually treated with immunomodulatory and/or immunosuppressive medications which can lead to an increased risk of infection. [2] [3] [4] However, to date the incidence of SARS-CoV-2 among all IBD patients appears to be comparable to that observed in the general population. [5] [6] [7] [8] To curb the ongoing pandemic caused by SARS-CoV-2 infection, vaccine development has been undertaken at an unprecedented pace and numerous candidates have either been authorized or are under development. 9 At present two vaccines are in wide clinical use in the US, the BNT162b2 mRNA Covid-19 Vaccine from Pfizer and the mRNA-1273 SARS-CoV-2 Vaccine from Moderna. 10, 11 Both of these vaccines have been shown to have greater than 90% efficacy and to date more than 100 million vaccines have been administered in the US. However, the seminal clinical trials excluded patients taking immunosuppressive medications or those with immunosuppressive conditions, thus the effectiveness in the population of patients with IBD is unknown.

To evaluate the effectiveness of SARS-CoV-2 vaccination in the IBD population and the potential impact of immunosuppressive medications, we identified a national cohort of IBD patients in the Veterans Health Administration (VHA). Our secondary aims were to evaluate the impact of vaccination on severe SARS-CoV-2 infection and all-cause mortality. The VHA is the largest integrated healthcare system in the US serving more than 9 million veterans every year 12 . As of April 22, 2021, over 2.1 million veterans have been fully vaccinated. 13 The VA has also established a database of all patients who have tested positive for SARS-CoV-2 and all medication records are maintained in a central pharmacy dataset making it an ideal health care system in which to conduct such a study.

This was a retrospective cohort study using VHA data from 12/18/2020 (index date), the date when the VHA began providing COVID-19 vaccinations to patients and extending through 4/20/21. The VHA contains granular demographic, laboratory, comorbidity, pharmacy, and other patient-level data that are centralized across 170 U.S. centers. We identified all patients with a diagnosis of ulcerative colitis or Crohn's disease prior to the index date using a previously validated algorithm based on administrative codes. 14 We included patients age ≥18 years who had not previously been diagnosed with SARS-CoV-2 infection in the VHA system (as determined by polymerase chain reaction [PCR] testing, antibody testing, or through natural language processing [NLP] of clinician notes 15 ), who were taking an IBD medication of interest (defined below), and who had at least 6 months of VHA outpatient visit data prior to the index date, thereby identifying patients who generally obtain care through the VHA. We excluded patients who received the Janssen COVID-19 vaccine given limited sample size and follow-up data.

Detailed demographic (age, sex, race), substance use (smoking status, alcohol abuse, drug abuse), and comorbidity data based on administrative codes (obesity, hypertension, diabetes, prior arrhythmia, heart failure, chronic obstructive pulmonary disease, renal failure, metastatic malignancy) 16 were obtained for each patient immediately prior to the index date. VHA center data were used to classify U.S. geographic region. To identify IBD medication exposures, we used VHA pharmacy records to identify prescription fills for medications of interest in a 3-month window prior to the index date, consistent with previously published methods. 16 Mutually exclusive IBD medication groups were categorized as follows: 5-aminosalicylic acid (5-ASA) alone, thiopurines (azathioprine or mercaptopurine, with or without 5-ASA), anti-tumor necrosis factor (anti-TNF) agents alone, anti-TNF agents plus immunomodulator therapy (thiopurines or methotrexate), vedolizumab, ustekinumab, tofacitinib, or methotrexate alone. We separately ascertained data on corticosteroid exposure in a 3-month window prior to the index date, which was treated as a binary variable. This included prescriptions for prednisone, prednisolone, methylprednisolone, or budesonide. Finally, we obtained COVID-19 vaccination data from the VHA Corporate Data Warehouse. This included the vaccine brand (Pfizer, Moderna, Janssen), the date of the first vaccination dose, and the date of the second vaccination dose.

The primary outcome was time to SARS-CoV-2 infection, which was determined from the results of polymerase chain reaction (PCR) testing performed in the VHA, as well as through an established NLP-based program that captures SARS-CoV-2 infections identified in non-VHA health systems. 15 Secondary outcomes included all-cause mortality, which was ascertained using the vital status file in the VHA dataset, as well as severe SARS-CoV-2 infection, which was defined as COVID-19-related hospitalization or death. This definition and methodology of severe SARS-CoV-2 infection is consistent with recently published literature using the VHA cohort. 16 

Descriptive statistics were reported as medians and interquartile ranges (IQRs) for continuous variables and as percentages for categorical variables. Cohort comparisons were made among unvaccinated and vaccinated individuals (either one or two doses received) using the Wilcoxon rank-sum or chi-square test, as indicated. To demonstrate the timing of vaccine administration relative to the index date, we plotted overlaid histograms of the first and second vaccine doses separately for each vaccine brand. For subsequent analyses, we utilized a concept of "effective vaccination status" where a patient was considered to be partially vaccinated starting 14 days after the first vaccine dose, and fully vaccinated starting 7 days after the second dose. These timepoints are consistent with estimates of protection from recent literature 17 as well as the seminal vaccination clinical trials. 10, 11 We reported raw proportions of patients who developed each primary and secondary outcome, stratified by effective vaccination status and vaccine manufacturer.

To address covariate imbalance and potential confounding between groups while preserving sample size and power, we chose an inverse probability weighted (IPW) modeling approach. First, a propensity score (PS) was created for the outcome of receiving any vaccination using all available patient characteristics, including U.S. geographic region, in a logistic regression model. Inverse probability weights were then computed for each patient as 1/(PS) for individuals who received a vaccine dose and 1/(1-PS) for individuals who did not. 18 The standardized mean differences (SMDs) between groups in both unadjusted and IPW-adjusted cohorts were then calculated and plotted for each variable, with an SMD +/-0.1 considered to represent adequate covariate balance. 19 To evaluate the association between effective vaccination status and the outcomes of interest, we used Cox proportional hazards regression. Effective vaccination status (unvaccinated, partially vaccinated, or fully vaccinated) was treated as a time-updating exposure in order to minimize the possibility of immortal time bias. 20, 21 Thus, the index time for a vaccinated individual would be the date of partial or full vaccination status, and risk adjustment would also account for unvaccinated time periods. For the primary outcome, we computed both unadjusted and IPW-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for the association between effective vaccination status (unvaccinated, partially vaccinated, fully vaccinated) and SARS-CoV-2 infection. The corresponding vaccine effectiveness was calculated as: ((1incidence vaccinated /incidence unvaccinated ) x 100). This was done for both partial vaccination and full vaccination. Observations were right censored at death during follow-up or at maximum follow-up. Given the possibility of differential impact of immunosuppressive IBD medications on vaccination effectiveness, we tested several a priori interaction terms, including between vaccination status and (1) steroid use, (2) 5-ASA alone versus immunosuppressive medications, and (3) anti-TNF use with immunomodulators or steroids versus other medications. We also tested for an interaction between vaccination status and vaccine manufacturer. For the secondary outcomes, unadjusted and IPW-adjusted estimates were similarly provided for the association between vaccination status and (1) severe SARS-CoV-2 infection and (2) all-cause mortality. Cox-adjusted survival curves were presented for each IPW-adjusted model and estimates of vaccine effectiveness in mitigating these outcomes were similarly provided using the approach detailed above. The proportional hazards assumption was tested using Schoenfeld residuals and no obvious violations were observed.

Due to the possibility of undiagnosed SARS-CoV-2 infection leading to mortality during follow-up, we performed additional analyses to evaluate the potential impact of this outcomes misclassification on the primary analysis. A random number generator was used to reclassify increasing percentages of patients who died during follow-up without a COVID-19 diagnosis as having been infected with SARS-CoV-2. IPW-adjusted Cox regression models were then performed for 5%, 10%, 15%, 20%, 25%, and 30% mortality event reclassifications. Adjusted HRs and 95% CIs were plotted for visual comparison.

Data management and analyses were performed using SAS (Carey, NC) and STATA 16.1/IC (College Station, TX). For all hypothesis tests we used a 5% alpha threshold for statistical significance. This study received Institutional Review Board approval from the Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.

After application of screening criteria, we identified 14,929 patients with IBD taking medications of interest prior to the index date. We excluded 232 patients who received the Janssen vaccine, yielding an analytic cohort of 14,697 patients. The majority of patients had ulcerative colitis (61.8%), with 54.8% taking 5-ASA alone, 19.9% anti-TNFs alone, and 10.7% thiopurines. Unvaccinated individuals were younger (median age 64 vs. 71, p<0.001) and had fewer comorbidities as compared to vaccinated individuals (each medical comorbidity p<0.001; Table 1 ). Vaccinated individuals were more likely to reside in the Northeast or Midwest as compared to unvaccinated individuals (p<0.001). Of the 7,321 patients who received at least one vaccine dose, 3,308 (45.2%) were given Pfizer and 4,013 (54.8%) Moderna. Through maximum follow-up, 91.2% of Pfizer (n=3,017) and 88.7% of Moderna patients (n=3,561) received both vaccine doses, with median duration between doses 21 days (IQR 21, 21) and 28 days (IQR 28, 28), respectively (Figure 1) .

After PS creation and IPW including all variables in Table 1 , the SMD for each variable was reduced to less than +/-0.05, representing excellent covariate balance (Figure 2) . Raw proportions of SARS-CoV-2 infection, accounting for time-updating effective vaccination status, are shown in Table 2 Table 2) . Of the 7 cases of infection occurring after full vaccination, 4 patients were taking 5-ASA alone, 1 a thiopurine with 5-ASA, 1 vedolizumab, and 1 tofacitinib. In both unadjusted and IPW-adjusted Cox regression analysis, full vaccination status but not partial vaccination status was protective against SARS-CoV-2 infection. For example, in the IPW-adjusted model, full vaccination was associated with a 69% reduction in the hazard of infection (HR 0.31, 95% CI 0.17-0.56, p<0.001) relative to unvaccinated individuals (Table 3; Figure 3A ). IPW-adjusted incidence rates for each vaccination status in the cohort are shown in Table 4 ; the corresponding vaccine effectiveness was 25.1% for partial vaccination status and 80.4% for full vaccination status. In a sensitivity analysis where increasing percentages of mortality events were randomly reclassified as SARS-CoV-2 infections, similar results were observed in the IPW-adjusted HRs for full vaccination versus unvaccinated status ( Figure 3D) 

During follow-up, individuals with an unvaccinated status had the numerically highest raw proportions of severe SARS-CoV-2 infection (47 [0.32%]) and all-cause mortality (97 [0.66%]), relative to individuals with partial or full vaccination status ( Table 2 ). In both unadjusted and IPW-adjusted Cox regression analyses, there was no significant association between vaccination status and (1) severe SARS-CoV-2 infection or (2) all-cause mortality (Table 3, Figure 3B /C). Although the associated Cox regression analyses were not statistically significant, the IPW-adjusted incidence rates and computed vaccine effectiveness in mitigating secondary outcomes are shown in Table 4 .

In this national cohort of IBD patients with diverse exposure to immunosuppressive agents treated in the VHA we found that full vaccination status, but not partial vaccination status, was associated with a 69% reduction in the hazard of SARS-CoV-2 infection. This corresponded to 80.4% vaccine effectiveness from 7 days after the 2 nd dose. Model estimates were not significantly impacted by use of different key immunosuppressive medication classes, though we note that no patients taking anti-TNF agents, ustekinumab, or methotrexate experienced SARS-CoV-2 infection >7 days after the 2 nd vaccine dose. While full vaccination status demonstrated the numerically lowest incidence rates of severe SARS-CoV-2 infection and all-cause mortality, these associations were not statistically significant.

Current data indicate that IBD patients do not inherently have an increased risk of developing SARS-CoV-2 infection or associated complications of COVID-19. [5] [6] [7] [8] 22 However, ~30% of patients with IBD are older than 65 years of age and about a third have comorbidities including those associated with adverse outcomes for COVID-19 such as cardiovascular diseases and diabetes. 22 It is imperative to control the spread of infection among this population. COVID-19 vaccines approved for use in the United States have gone through development at an unprecedented pace and have been shown to be very efficacious in clinical trials. 10, 11 However, the Pfizer vaccine did not include patients who were undergoing "treatment with immunosuppressive therapy or diagnosed with an immunocompromising condition." 10 Similarly, the Moderna trial excluded those with "immunosuppressive or immunodeficient state, [or those] receiving systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to screening." 11 This has resulted in a lack of data on the impact of immune-modifying therapies used in the management of IBD on the effectiveness of vaccinations, and potential reluctance to pursue vaccination in this setting. Two recent studies have shown that immunosuppressive medications may affect the serological response to SARS-CoV2 and to vaccinations. Kennedy et al found that infliximab is associated with attenuated serological responses to SARS-CoV-2 that was further blunted by concomitant immunomodulators use. 23 Wong et al reported 100% seropositivity following two-dose Pfizer and Moderna COVID-19 vaccination among IBD patients on biological therapies. 24 However, despite achieving antibody levels consistent with those thought to confer protection, they also found an association of lower antibody levels in patients on vedolizumab for all antibodies tested and with anti-TNFs for anti-RBD total Ig only. Therefore, it is imperative to obtain real-world data on vaccination outcomes in patients with IBD to help inform patients and their treating physicians.

In this study we found that completion of a vaccination series was effective in reducing SARS-CoV-2 infection among IBD patients with diverse exposure to immunosuppressive medications. About 45% of patients received the Pfizer vaccine with the remainder receiving Moderna, and there were no differences in effectiveness noted between the vaccines. The level of protection observed among IBD patients in this study was slightly lower than that reported in the clinical trials comprised of a more general population, 10, 11 with 80.4% effectiveness versus >90% using similar metrics in the trials. As detailed in the limitations below, there are several reasons why the estimate of vaccine effectiveness in this study may be conservative, however there are also biologically plausible explanations for reduced effectiveness in an IBD cohort. Recent studies as highlighted above have also shown that the serological response to SARS-COV 2 and the vaccines may be impacted by IBD medications. Additionally, partial vaccination status after receiving a single vaccine dose alone was not significantly associated with reductions in SARS-CoV-2 infection relative to an unvaccinated status, in contrast to prior data from a more general cohort, 17 underscoring the importance of completion of the vaccination series in IBD patients. Importantly, we did not identify any significant interactions between vaccination and key immunosuppression medication classes, suggesting that SARS-CoV-2 vaccine effectiveness is similar in IBD patients regardless of the particular immunosuppressive agents being used. However, of the patients taking immunosuppressive medications the most common class was anti-TNF agents, and there was not a single case of SARS-CoV-2 infection identified in fully vaccinated patients in this group. Finally, while we did not identify a statistically significant difference in the secondary outcomes of severe SARS-CoV-2 infection and all-cause mortality, the incidence rates for these outcomes were numerically lowest in the fully vaccinated group. Future studies with larger sample size and/or longer follow-up are needed to evaluate this further.

Our findings have strong and immediate clinical importance. Patient willingness to receive vaccination is based upon the perceived effectiveness of the vaccine as well as healthcare provider recommendations. 21 This study supports the effectiveness of vaccination in patients with IBD taking diverse immunosuppressive agents and may allay fears in this regard. While this prospect requires further study, similar results may be expected in non-IBD patients who are taking similar immunosuppression agents, where patient willingness to pursue vaccination may be increased through demonstration of vaccine effectiveness.

Major strengths of this study include the use of a national cohort of IBD patients followed in the VHA system, serving approximately 9 million veterans every year. 12 Every patient in the VHA has a SARS-CoV-2 status designation in the electronic health record (positive, negative, or not tested), even if diagnosed to be positive outside the VHA. The VHA has also developed a central database which updates all SARS-CoV-2 diagnoses and vaccination status with more than 2.1 million veterans fully vaccinated to date. These features contribute to high confidence that vaccination events and SARS-CoV-2 diagnoses have been captured with minimal misclassification in this cohort. An additional strength of this study is the use of nationwide VHA Pharmacy records for gathering IBD medication data. The VHA has a central pharmacy database, meaning that medications prescribed at different VA centers are linked for a given patient, thus decreasing the chance of missing or misclassified prescribed medications.

Notwithstanding, we acknowledge several important limitations in this study. First, although we demonstrated excellent IPW-adjusted covariate balancing across a range of important patient-level and geographic predictors, there remains a possibility of residual confounding. Second, there are inherent external validity limitations to the VHA cohort, as it is largely comprised of an older male population. Hence, there is also a higher proportion of UC patients as older-onset UC is more common than CD, with rates higher in elderly men than women. 25 However, it is not clear that these features would be salient contributors to differences in vaccine effectiveness. There may also be external validity limitations as applied to non-IBD patients who are taking immunosuppressive medications, as this study was intentionally focused on the IBD population where there may be independent influences of the condition itself on vaccination effectiveness. Future studies may seek to address vaccine effectiveness in immunosuppressed patients more generally. Third, patients are not proactively screened for SARS-CoV-2 in the VHA but rather tested when symptomatic or for preventative measures such as before an elective procedure. Hence, our patient population could be biased toward symptomatic COVID-19 patients and could miss a substantial proportion of asymptomatic patients. This potential misclassification would likely lead to an underestimate in effect size, as vaccinated individuals may be more proactive with regard to their healthcare and therefore more likely to seek SARS-CoV-2 testing for any reason as compared to unvaccinated individuals, though it is difficult to be certain without a systemic approach to testing which may in part explain the lower efficacy rates seen in our study. Furthermore, the robust VHA approach to capture both VHA and non-VHA diagnosed SARS-CoV-2 infections (via NLP) should serve to minimize misclassification. Fourth, patients vaccinated outside the VHA system could lead to exposure misclassification, however this would be expected to bias estimates towards a null hypothesis, suggesting that the observed results may again be conservative. Finally, there is the possibility of misclassification of medication exposures, and records of medications prescribed outside the VHA may be incomplete. This issue may be most salient for steroid use, which may be dynamic over even short periods of time. However, veterans have a strong adherence in utilizing the VHA pharmacy and depending upon their benefit status the medications are typically free or cheaper than non-VHA alternatives. 22, 23 Furthermore, we used a narrow ascertainment window for medications prior to the index date and given the relatively short follow-up time the impact of medication exposure misclassification in this study would be minimal.

In conclusion, in a large national cohort of IBD patients with diverse exposure to immunosuppressive agents we found that full vaccination, but not partial vaccination, was significantly associated with reduced SARS-CoV-2 infection with an 80.4% effectiveness >7 days after the 2 nd dose. Out of 6,578 patients with full vaccination status there were no SARS-CoV-2 infections identified among those taking anti-TNF agents, ustekinumab, or methotrexate. To the best of our knowledge, this is the first study to report these findings and they should provide positive reinforcement to IBD patients on immunosuppressive agents who may otherwise be reluctant to receive vaccination. 

COVID-19 Mortality Overview

Pathway paradigms revealed from the genetics of inflammatory bowel disease

Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases

Infections and IBD

Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts

novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases

SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California

Are Patients With Inflammatory Bowel Disease at an Increased Risk of Developing SARS-CoV-2 than Patients Without Inflammatory Bowel Disease? Results From a Nationwide Veterans' Affairs Cohort Study

SARS-CoV-2 vaccines in development

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Affairs USDoV. Department of Veterans Affairs COVID-19 National Summary

Overall and comparative risk of herpes zoster with pharmacotherapy for inflammatory bowel diseases: a nationwide cohort study

A Natural Language Processing System for National COVID-19 Surveillance in the US Department of Veterans Affairs

Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies

Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples

Issues regarding 'immortal time'in the analysis of the treatment effects in observational studies

Immortal time bias in observational studies of time-to-event outcomes

Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies

We would like to thank Rebecca A. Hubbard and James D. Lewis for useful conversations that informed the methodological approach in this study.

J o u r n a l P r e -p r o o f Tables:  Table 1